SCHEMBL24378634

SCHEMBL24378634

CS(=O)(=O)N1CCN(C(=O)c2cc3nc(Cl)cc(N4CCOCC4)n3n2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.43
ALDH1A1 P00352 7/20 0.43
HSD17B10 Q99714 2/20 0.43
POLB P06746 1/20 0.43
BLM P54132 1/20 0.43
KDM4E B2RXH2 3/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 2/20 0.40
RAB9A P51151 1/20 0.40
PIK3CD O00329 2/20 0.39
PIK3CA P42336 4/20 0.38
MTOR P42345 3/20 0.38
ESR2 Q92731 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 1/20 0.37
PIK3R1 P27986 2/20 0.37
DPP4 P27487 1/20 0.37
DPP8 Q6V1X1 1/20 0.37
DPP9 Q86TI2 1/20 0.37
PIK3CB P42338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27009137 0.88 HPGD (0.53) HPGDALDH1A1HSD17B10POLBBLM
SCHEMBL27009144 0.87 HPGD (0.49) HPGDALDH1A1HSD17B10POLBBLM
SCHEMBL27009142 0.84 HPGD (0.43) HPGDALDH1A1HSD17B10POLBBLM
SCHEMBL29547619 0.80 HPGD (0.48) HPGDALDH1A1HSD17B10POLBBLM
SCHEMBL3990715 0.80 PIK3CA (0.49) HPGDALDH1A1MAPK1TSHRPIK3CD
SCHEMBL22718319 0.79 KMO (0.44) HPGDALDH1A1HSD17B10POLBBLM
SCHEMBL24378570 0.78 PIK3CA (0.55) PIK3CDPIK3CAMTORPIK3R1PIK3CB
SCHEMBL24378563 0.76 ABCB1 (0.44) HPGDALDH1A1HSD17B10KDM4EMAPK1
SCHEMBL13815641 0.74 PIK3CA (0.45) HPGDALDH1A1HSD17B10POLBKDM4E
SCHEMBL24378656 0.72 ALDH1A1 (0.42) HPGDALDH1A1HSD17B10POLBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC 2024-01-18 US disclosed
EP-4229063-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME Therapeutics LLC (US) 2023-08-23 EP disclosed
WO-2022086993-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC (US) 2022-04-28 WO disclosed
WO-2022086993-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME TME THERAPEUTICS LLC (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018151-A1 NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME PIKFYVE, PIK3CD, PIK3R5 HPGD 4676/4885ALDH1A1 4878/4885HSD17B10 3432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.